Please wait while the formulary information is being retrieved.
NILANDRON (NILUTAMIDE)
- Metastatic prostate carcinoma
150 mg tablet
- 1 tablet (150 mg) by oral route once daily
150 mg tablet
- 1 tablet (150 mg) by oral route once daily
150 mg tablet
- 1 tablet (150 mg) by oral route once daily
Metastatic prostate carcinoma
- 1 tablet (150 mg) by oral route once daily
- 2 tablets (300 mg) by oral route once daily
- 2 tablets (300 mg) by oral route once daily for 30 days
- natalizumab
- Tysabri
Contraindicated
- None
Severe
Moderate
- None
- Interstitial pneumonitis
- Respiratory depression
- Severe hepatic disease
Contraindicated
- Abnormal hepatic function tests
- Drug-induced hepatitis
- Hyperbilirubinemia
Severe
Moderate
- None
NILANDRON (NILUTAMIDE)
- Metastatic prostate carcinoma
- None
- Drug-induced hot flash
- Erectile dysfunction
- Libido changes
- Nausea
- Night blindness
More Frequent
Severe
Less Severe
- Drug-induced hepatitis
- Dyspnea
- Hypertension
- Interstitial pneumonitis
- Leukopenia
- Urinary tract infection
- Acquired chromatopsia
- Anorexia
- Constipation
- Diarrhea
- Dizziness
- Photophobia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
Nilutamide
No pediatric safety and efficacy. Indicated only for metastatic prostate cancer.
- 1 Day – 18 Years
- No pediatric safety and efficacy. Indicated only for metastatic prostate cancer.
Management or Monitoring Precaution
None
Nilutamide
- Severity Level:
C
- Additional Notes: Not indicated for female use
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Nilutamide
Not indicated in females
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Not indicated in females |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Nilutamide
Gastrointestinal-Risk of constipation. Neuro/Psych-Risk of dizziness.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Rarely, nilutamide has caused severe (sometimes fatal) lung problems (interstitial pneumonitis). Seek immediate medical attention if you develop symptoms of lung problems (such as cough, trouble breathing, chest pain, fever). Lung problems can happen at any time while you are taking nilutamide, but they occur most often during the first 3 months of treatment.<br /><br />Your doctor will tell you whether to stop or continue nilutamide. Your doctor may have you get a chest X-ray and breathing tests before you start nilutamide.
| Metastatic prostate carcinoma | |
| C61 | Malignant neoplasm of prostate |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
Formulary Reference Tool